Health Goal: Healthy Aging

Every other article in this Healthy Aging series has covered a supplement ingredient and found, in every single case, evidence that’s real but modest, contested, or genuinely thinner than the marketing implies. This article exists to provide honest context for that pattern: the interventions with the strongest, largest, most consistently replicated human evidence for healthy aging outcomes — reduced all-cause mortality, preserved physical function, lower chronic disease risk — are not things sold in a bottle. They’re resistance exercise, adequate sleep, and a specific, well-studied dietary pattern. None of that is a marketing angle this site can sell against; it’s simply the most honest thing we can tell a reader who wants to know what actually works.

The short version

• Resistance (strength) training has some of the strongest, most consistent human evidence in the entire healthy-aging space — regularly associated with lower all-cause mortality, better preserved muscle mass and bone density, reduced fall risk, and maintained functional independence in older adults, including those who are already frail.
• A global expert consensus on exercise for healthy longevity in older adults recommends roughly 150–300 minutes per week of moderate-intensity aerobic activity, combined with 2–3 resistance-training sessions per week — and mortality-reduction research specifically found benefits from resistance training plateauing around 120 minutes per week, meaning meaningful benefit doesn’t require an extreme time commitment.
• A large NIH-AARP cohort study (over 380,000 U.S. adults, 27,799 deaths recorded over roughly a decade of follow-up) found that closer adherence to a Mediterranean dietary pattern (plant-forward, olive oil, fish, legumes, whole grains, moderate wine) was associated with a 20% reduction in all-cause mortality — one of the largest single studies of a dietary pattern’s association with longevity available, in a U.S. population specifically (relevant since much Mediterranean-diet research is conducted in Mediterranean countries themselves).
• Sleep duration in mid-to-late life has a documented, non-linear relationship with healthy aging outcomes: both too little and too much matter. A 25-year follow-up of the Whitehall II cohort study (over 10,000 UK civil servants) found that sleeping 5 hours or less at age 50 was associated with a 20% increased risk of developing a first chronic disease, and that both very short sleep and sleep of 9+ hours at ages 60 and 70 were associated with increased risk of multimorbidity (having multiple chronic conditions at once). The National Institute on Aging’s general recommendation for older adults is the same as for younger adults: roughly 7–9 hours nightly.
• None of this is a reason to dismiss supplements outright — several ingredients covered elsewhere in this series (collagen for joint health, for instance) have real, if modest, supporting evidence. The point of this article is comparative honesty: when a reader is deciding where to put limited time, money, or attention for healthy aging, the lifestyle interventions below currently have larger, more consistent, and more directly outcome-focused (not just biomarker-focused) evidence behind them than any single ingredient this series has covered.

Resistance training: the single best-evidenced intervention in this category

Of everything covered across this entire Healthy Aging series, resistance training has the most consistent, large-scale human evidence for the actual outcomes people care about — not just a biomarker moving in a favorable direction, but measured reductions in death and preserved ability to function independently.

A 2024 global expert consensus process (the International Conference on Frailty and Sarcopenia Research) reviewed the accumulated evidence and issued specific, practical exercise recommendations for healthy longevity in older adults: roughly 150–300 minutes per week of moderate-intensity aerobic activity, combined with 2–3 sessions of resistance training weekly. Separately, mortality-focused research has found that moderate weekly resistance training is associated with measurably lower all-cause mortality, with the greatest risk reduction observed around 120 minutes of resistance training per week — a real but genuinely achievable weekly commitment, not an extreme athletic regimen.

The mechanisms behind this are reasonably well understood and don’t rely on a single pathway: exercise reduces oxidative damage, chronic low-grade inflammation, and mitochondrial dysfunction — three processes independently implicated in cellular aging — while increasing brain-derived neurotrophic factor (BDNF), a protein supporting both physical and cognitive resilience. There’s also a growing body of research on a “muscle-brain axis,” where skeletal muscle contraction releases signaling proteins (myokines) that appear to support brain function and neuroplasticity, a genuinely different and more direct systemic mechanism than most supplement ingredients in this category can currently point to.

For older adults specifically — including those who are already frail, have sarcopenia (age-related muscle loss), or have osteoporosis — progressive resistance training has documented benefits for functional independence and fall-risk reduction, which are among the most consequential, quality-of-life-determining outcomes in aging research, not abstract biomarkers.

Diet: the Mediterranean pattern’s evidence base, at real scale

Dietary pattern research is harder to run as a clean randomized trial than a pill (people can’t be blinded to what they’re eating, and dietary patterns are followed for years or decades, not weeks), which makes large, long-term cohort studies especially valuable here. One of the largest is the NIH-AARP Diet and Health Study: over 380,000 U.S. adults (214,284 men, 166,012 women) followed for all-cause mortality from 1995 to 2005, during which 27,799 deaths were recorded. Closer adherence to a Mediterranean dietary pattern — characterized by high intake of vegetables, fruits, whole grains, legumes, nuts, and olive oil, moderate fish and dairy, and limited red meat — was associated with a 20% reduction in all-cause mortality risk, with the association holding across both men and women in this specifically American population (worth noting, since a lot of Mediterranean-diet research understandably comes from Mediterranean-region cohorts, where the dietary pattern is a native, everyday eating style rather than an adopted change).

Beyond the single large cohort study above, the broader research literature — including systematic reviews and meta-analyses in older-adult populations specifically — consistently links Mediterranean-pattern adherence to reduced cardiovascular mortality and fewer non-fatal cardiovascular events, alongside proposed mechanisms including reduced inflammation and oxidative stress, better vascular function, and effects on processes tied to cellular senescence. This is a notably similar mechanistic story to several supplement ingredients covered elsewhere in this series (resveratrol’s proposed anti-inflammatory pathway, for instance) — the meaningful difference is that the dietary-pattern evidence has been demonstrated at outcome level (actual mortality, actual cardiovascular events), in far larger populations, over much longer follow-up periods, than the supplement evidence typically achieves.

Sleep: an underappreciated piece, with a genuinely two-sided finding

Sleep is easy to treat as a wellness afterthought next to diet and exercise, but the evidence connecting sleep duration in mid-to-late life to healthy aging outcomes is substantial and worth taking seriously in its own right. A 25-year follow-up of the Whitehall II cohort study — a well-established UK research cohort of over 10,000 civil servants, with sleep duration self-reported six separate times between 1985 and 2016 — found that people sleeping 5 hours or less per night at age 50 had a 20% higher risk of developing a first chronic disease compared to those sleeping around 7 hours, and that short sleep was further associated with a higher risk of multimorbidity (accumulating multiple chronic conditions) among those who developed a first disease.

The finding is genuinely two-sided, not simply “more sleep is better”: sleeping 9 or more hours per night at ages 60 and 70 (though notably not at age 50) was also associated with increased multimorbidity risk in the same study. This U-shaped pattern — both too little and too much sleep associated with worse outcomes — recurs across multiple sleep-and-aging studies, and it’s a useful corrective to a simple “sleep more” message. The National Institute on Aging’s general guidance reflects this: older adults need roughly the same amount of sleep as younger adults, about 7 to 9 hours nightly, not more and not dramatically less. The NIA also notes that specific, treatable factors — insomnia, menopause-related sleep disruption, and sleep apnea — commonly interfere with older adults getting adequate sleep, which is directly relevant to our companion article on medical causes of persistent fatigue in the Energy & Focus series, where sleep apnea specifically is covered in more depth.

Why this comparison matters for how to read the rest of this category

Every ingredient-focused article in this Healthy Aging series has arrived at a similar structural finding: a plausible mechanism, some positive human data, but a gap between what’s been demonstrated and what marketing implies — collagen’s skin claims resting on a contested, funding-influenced evidence base; NAD+ precursors reliably raising a biomarker without yet showing downstream clinical benefit at scale; resveratrol’s sirtuin-activation story failing to survive rigorous scrutiny despite a $720 million pharmaceutical bet on it. This article isn’t a criticism of any of those ingredients specifically — it’s the comparison point that makes their limitations legible. Resistance training, Mediterranean-pattern eating, and adequate (not excessive) sleep each have evidence bases built on actual outcomes (mortality, chronic disease incidence, functional independence) in populations numbering in the hundreds of thousands, over years or decades — a different tier of evidence than most single-ingredient supplement research currently achieves, for reasons that are partly structural (a lifestyle pattern is easier to study at massive scale via cohort studies than a specific compound at a specific dose) and partly a real reflection of effect size.

What we could not check

• We did not conduct a systematic review of exercise, diet, or sleep research for healthy aging — this article highlights three well-evidenced interventions with notably large or long-running supporting studies, not an exhaustive survey of every lifestyle factor relevant to aging (e.g., social connection, stress management, and smoking/alcohol cessation all have their own substantial literatures not covered here).
• We did not independently access the full text of the NIH-AARP Mediterranean diet study or the Whitehall II sleep study — key figures (20% mortality reduction; 20% increased first-chronic-disease risk; participant and death counts) are drawn from abstracts and secondary summaries, not a full methods-and-results read.
• We did not review the ICFSR global exercise consensus statement’s full methodology — its headline dosing recommendations (150–300 min aerobic, 2–3 resistance sessions weekly) are drawn from secondary summaries.
• This article does not provide individualized exercise, diet, or sleep guidance — readers with existing health conditions, injuries, or sleep disorders should consult a doctor before making significant changes, particularly for exercise programs in the context of frailty or existing cardiovascular disease.

Our rating, and why

Not applicable. This is a non-product article by design — its purpose is to give honest, evidence-based context for a category where the best-evidenced intervention for the outcomes readers actually care about usually isn’t something this site, or any retailer, sells. Presenting this comparison directly, rather than only ever discussing supplements, is consistent with this site’s Editorial Policy and with genuine reader service: someone asking “what actually slows aging” deserves the honest answer, even when that answer doesn’t lead toward a product.

---

Sources

1. Mitrou PN, Kipnis V, Thiébaut ACM, et al. Mediterranean Dietary Pattern and Prediction of All-Cause Mortality in a US Population: Results From the NIH-AARP Diet and Health Study. Archives of Internal Medicine. 2007;167(22):2461-2468. (read via abstract and secondary summaries)
2. Sabia S, Dugravot A, Léger D, Ben Hassen C, Kivimaki M, Singh-Manoux A. Association of sleep duration at age 50, 60, and 70 years with risk of multimorbidity in the UK: 25-year follow-up of the Whitehall II cohort study. PLOS Medicine. 2022;19(10):e1004109. (read via abstract and secondary summaries)
3. National Institute on Aging (NIA). Sleep and 6 Healthy Sleep Habits for Older Adults. https://www.nia.nih.gov/health/sleep (secondary summary of NIA guidance)
4. Global consensus on optimal exercise recommendations for enhancing healthy longevity in older adults (International Conference on Frailty and Sarcopenia Research, ICFSR). PMID: 39743381. https://pubmed.ncbi.nlm.nih.gov/39743381/ (read via abstract and secondary summaries)
5. Evidence-based exercise enhances healthy aging. PMC (secondary summary — resistance-training mortality dose-response and mechanism discussion)

Resveratrol is the best case study in this entire category for how a plausible early hypothesis can outlive the research that was supposed to confirm it. It has a real, traceable origin story (the “French Paradox”), a genuine celebrity scientific champion, a $720 million pharmaceutical acquisition built on its promise, and — after all of that — a 2024 systematic review of the accumulated human clinical trial evidence that concluded there is “currently no conclusive clinical evidence to advocate its recommendation in any healthcare setting.” Understanding how that gap opened up is more useful to a reader than any single verdict on the ingredient itself, because the same pattern — an intriguing epidemiological observation, promising animal data, and a stalled human evidence base — shows up across most of the “antioxidant” and polyphenol category this term covers.

The short version

• Resveratrol’s origin story is real: the “French Paradox” is a genuine, published epidemiological observation — French populations showing comparatively low rates of coronary heart disease despite a diet relatively high in saturated fat, a pattern researchers in the 1990s proposed might be partly explained by red wine consumption and its resveratrol content.
• The hypothesis escalated dramatically in 2003, when researcher David Sinclair reported that resveratrol activated a longevity-associated gene pathway (sirtuins) in yeast, later extended to worms, flies, and mice — a genuinely exciting basic-science finding that suggested a “starvation-free” way to trigger some of the same cellular pathways activated by caloric restriction, itself a well-studied longevity intervention in animals.
• That basic-science excitement translated into real money: GSK acquired Sinclair’s company, Sirtris Pharmaceuticals, for $720 million in 2008, specifically to develop resveratrol-based drugs. This is a useful, concrete illustration of how seriously the pharmaceutical industry took the underlying science at the time — this wasn’t purely a supplement-industry marketing invention.
• It didn’t hold up. GSK discontinued its lead resveratrol drug candidate (SRT501) in 2010 after safety concerns and an inability to replicate the preclinical results in human trials, and other research groups — including a 2011 Nature paper and separate Pfizer researchers — published findings challenging whether resveratrol directly activates sirtuins the way originally proposed at all. Sirtris was fully shut down by 2013.
• A major, separate practical problem: resveratrol has genuinely poor oral bioavailability in humans. Absorption from the gut is actually reasonably good (around 75%), but the compound is then very rapidly metabolized by the liver and intestines (via glucuronidation and sulfation) into inactive forms before it can reach meaningful circulating levels — relative bioavailability of the active, unmetabolized compound is commonly reported at under 1%. This is a well-documented pharmacokinetic finding, not a fringe theory, and it’s a major reason the encouraging cell-culture and animal data hasn’t translated cleanly to humans at typical oral doses.
• Current human evidence, per a 2024 systematic review of resveratrol clinical trials, is mixed on intermediate biomarkers (some trials show improvements in inflammatory markers, vascular function, or insulin sensitivity) but shows no robust, replicated evidence for the outcomes the marketing actually implies — longevity, mortality reduction, or “anti-aging” in any measurable sense. No resveratrol trial to date has been large enough or long enough to actually test a mortality or lifespan outcome in humans; the same review found that over 90% of published resveratrol trials measured short-term biomarkers instead, and fewer than 5% enrolled more than 500 participants.

The French Paradox: a real observation, stretched well past what it showed

The “French Paradox” refers to a genuine pattern noted by epidemiologists: comparatively low rates of coronary heart disease in French populations despite a diet with substantial saturated fat intake. Red wine consumption was proposed as one possible contributing factor, and resveratrol — a compound found in grape skins and, therefore, red wine — became a leading candidate explanation. It’s worth being precise about what this observation actually was and wasn’t: it was a population-level correlation with multiple plausible explanations (diet pattern overall, portion sizes, different reporting/diagnostic practices, other lifestyle factors), not a controlled experiment isolating resveratrol as a cause. That distinction — real observation, unproven single-ingredient explanation — is the seed of everything that followed.

From yeast to a $720 million drug company, and back down again

In 2003, David Sinclair’s research found that resveratrol activated sirtuins — a family of proteins linked to the cellular effects of caloric restriction, itself a longevity intervention with a much longer and more consistent track record in animal studies — in yeast. This extended to positive results in nematode worms, fruit flies, and mice, generating substantial excitement that resveratrol might offer a “caloric-restriction mimetic” effect without requiring actual caloric restriction.

The pharmaceutical industry took this seriously enough to invest at real scale: GSK acquired Sirtris Pharmaceuticals, the company Sinclair co-founded, for $720 million in 2008 — nearly double its public market valuation at the time — specifically to develop resveratrol-derived drug candidates. This is worth including precisely because it demonstrates the hypothesis was taken seriously by sophisticated, financially motivated scientific reviewers, not dismissed as supplement-industry hype from the outset.

It then fell apart in stages. GSK discontinued development of its lead candidate, SRT501, in 2010, following safety concerns (including kidney-related adverse events observed in a multiple myeloma trial) and an inability to replicate the preclinical potency data in humans. Separately, a 2011 paper in Nature and independent work from Pfizer researchers challenged the core mechanistic claim, presenting evidence that resveratrol did not directly activate SIRT1 the way originally proposed, and that some of the original activation findings may have been an artifact of the specific experimental assay used. Sirtris was fully shut down by 2013.

None of this means resveratrol “doesn’t work” in some absolute sense — but it’s a concrete, well-documented example of how a promising basic-science mechanism, even one serious enough to attract a nine-figure pharmaceutical investment, can fail to survive contact with rigorous human trials. It’s a useful pattern to recognize, because it’s not unique to resveratrol; several other ingredients in this “healthy aging” category (NAD+ precursors among them) show an early version of the same shape.

The bioavailability problem: a real, separate reason the human data disappoints

Independent of the sirtuin-mechanism dispute, resveratrol has a well-documented pharmacokinetic problem that would limit its effectiveness even if the underlying biological hypothesis were fully correct. Oral absorption from the gut is actually reasonably efficient, around 75% — but the compound is then very rapidly metabolized by the liver and intestinal wall (primarily via glucuronidation and sulfation) into inactive metabolite forms before much of it ever reaches systemic circulation intact. The commonly cited figure for resveratrol’s relative oral bioavailability — the fraction of an oral dose that reaches the bloodstream in active form — is under 1%. There’s also documented wide individual variability in this process, plausibly influenced by differences in gut microbiota composition between people. Multiple companies have developed alternative formulations (micronized particles, lipid-based delivery systems, sublingual lozenges) specifically attempting to work around this bioavailability ceiling — a real, ongoing area of pharmaceutical development, though not yet something with the same depth of independent human outcome data as standard resveratrol itself.

What the current human trial evidence actually shows

A 2024 systematic review of resveratrol clinical trials (published in the International Journal of Molecular Sciences) reviewed the accumulated human research and reached a notably blunt conclusion: despite resveratrol being proposed as beneficial across numerous conditions, “there is currently no conclusive clinical evidence to advocate its recommendation in any healthcare setting.” The same body of research shows a genuine mixed picture at the level of intermediate biomarkers — some trials report improvements in inflammatory markers or aspects of metabolic function (insulin sensitivity, vascular measures) — but these are surrogate outcomes, not demonstrated reductions in disease or mortality.

The scale problem compounds this: detecting even a modest (5%) relative reduction in all-cause mortality in an older-adult population would require a trial with tens of thousands of participants followed for years — a study design no resveratrol trial has come close to. A 2024 review estimated that over 90% of published resveratrol trials measured short-term biomarkers rather than any hard clinical or mortality outcome, and fewer than 5% enrolled more than 500 participants. In plain terms: the trials needed to actually test the longevity claim resveratrol is marketed on largely haven’t been run, and the ones that have been run mostly weren’t designed to answer that question in the first place.

What “antioxidant supplement” framing adds (and obscures)

Resveratrol is frequently marketed under a broader “antioxidant” umbrella alongside compounds like other polyphenols, and this framing is worth naming as its own separate issue. “Antioxidant” describes a chemical property (the ability to neutralize reactive oxygen species in a test tube), not a demonstrated health outcome in a living person — oxidative stress is a real and measurable biological process linked to aging and disease, but decades of antioxidant supplement research (well beyond resveratrol specifically, including large trials of vitamin E and beta-carotene) has generally failed to show that supplementing antioxidant compounds translates into the disease-prevention or longevity benefits the “fights free radicals” marketing language implies, and some large trials of specific antioxidant supplements have found unexpected harms in certain populations. This broader pattern is relevant context for evaluating any product in this category that leans on “antioxidant” language as its primary evidence claim, rather than citing specific outcome data for the specific compound at the specific dose used.

What we could not check

• We did not independently pull and read the full text of the 2024 resveratrol systematic review (International Journal of Molecular Sciences) — its topline conclusion and trial-count statistics are drawn from its abstract and secondary summaries, not a full methods read.
• We did not independently verify the specific GSK/Sirtris financial and regulatory timeline (the $720 million acquisition figure, the SRT501 discontinuation circumstances, the Sirtris shutdown date) beyond secondary business- and science-press reporting — we have not read GSK’s own primary corporate disclosures or the original clinical trial safety data directly.
• We did not review the newer bioavailability-enhanced resveratrol formulations (micronized, lipid-based, sublingual) in any depth — these are named as an active area of development, not evaluated as evidence for or against.
• We did not conduct a broader review of antioxidant-supplement trial evidence beyond resveratrol specifically (vitamin E, beta-carotene, etc.) — referenced briefly for context on the “antioxidant” framing issue, not covered in the depth this article gives resveratrol itself.

Our rating, and why

Limited. The mechanistic story that launched this category (sirtuin activation, a caloric-restriction mimetic effect) has not held up cleanly under independent scrutiny, and a separate, well-documented bioavailability problem limits how much orally administered resveratrol ever reaches active circulation regardless of the mechanism question. Human trials show a genuinely mixed picture on short-term biomarkers — not nothing, but not the longevity or disease-prevention outcome the category is marketed on — and no trial has been designed at the scale needed to actually test that outcome. Limited, rather than Anecdotal, because there is real randomized human trial data showing some biomarker effects; not higher than Limited because the specific claims most commonly made for this ingredient (longevity, “anti-aging,” slowing cellular decline) remain unsupported by any completed human outcome trial.

---

Sources

1. Resveratrol for the Management of Human Health: How Far Have We Come? A Systematic Review of Resveratrol Clinical Trials to Highlight Gaps and Opportunities. International Journal of Molecular Sciences. 2024;25(2):747. https://www.mdpi.com/1422-0067/25/2/747 (read via abstract and secondary summaries)
2. Walle T. Bioavailability of resveratrol. Annals of the New York Academy of Sciences. 2011;1215:9-15. (read via abstract and secondary summaries)
3. Walle T, et al. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metabolism and Disposition. PMID: 15333514. https://pubmed.ncbi.nlm.nih.gov/15333514/ (read via abstract and secondary summaries)
4. Business and science press coverage of the GSK/Sirtris acquisition and SRT501 discontinuation (2008–2013), including Fierce Biotech and The New Republic reporting. Primary GSK corporate disclosures not independently accessed — see editorial notes.
5. Base R, et al. Resveratrol: French paradox revisited. PMID: 22822401. https://pubmed.ncbi.nlm.nih.gov/22822401/ (read via abstract only)

“Anti-aging” is one of the most-used phrases in the supplement industry and also one of the most legally loaded, because aging itself sits in an unusual spot in FDA and FTC rules: it’s not a disease, but claims about reversing, slowing, or repairing its effects can slide into disease-claim territory faster than most marketers realize — and faster than most readers realize either. This article isn’t a product review. It’s a plain-language walkthrough of the actual federal rule that draws this line, plus two concrete enforcement cases showing what happens when a company crosses it, so that both this site’s own future reviews and its readers evaluating other brands have a real framework rather than a vague sense that “some claims are too good to be true.”

The short version

• Aging itself is not classified as a disease under FDA’s own regulation — but claims about affecting the abnormal effects of aging, or specific age-related conditions, can legally count as disease claims, which pushes a product out of “dietary supplement” territory and into “unapproved drug” territory.
• The actual rule is 21 CFR 101.93, which distinguishes permitted “structure/function” claims (describing how an ingredient supports the body’s normal structure or function) from prohibited “disease claims” (describing an effect on a disease, its symptoms, or “an abnormal condition associated with a natural process” when that condition is uncommon or can cause significant or permanent harm) — language that maps directly onto how “anti-aging” products are often marketed.
• A real, concrete example: in 2020, the FTC settled charges against the sellers of a supplement called ReJuvenation, whose marketing claimed the product could “reverse the aging process,” repair damage from heart attacks, Alzheimer’s, Parkinson’s, and Crohn’s disease, and increase human growth hormone and stem cell counts in the body. The settlement required $660,000 in consumer refunds and separate judgments of $993,416 and $2.4 million against the individual defendants (both substantially suspended contingent on smaller payments), plus a permanent prohibition on making such claims without scientific substantiation.
• The specific language matters more than the general topic. A claim like “supports skin’s natural collagen production” is a permitted structure/function claim. A claim like “reverses the visible signs of aging” or “repairs cellular damage” risks crossing into disease-claim or drug-claim territory, particularly when paired with references to named conditions, before/after photography implying treatment, or citations to disease-focused research.
• This is why this site’s own editorial approach treats “anti-aging” framing as a flag requiring extra care, not a reason to avoid the category — plenty of well-evidenced, honestly marketed structure/function claims exist in this space (see our companion articles on collagen and NAD+ precursors); the issue is specifically the gap between what’s legally and scientifically defensible and what more aggressive marketing implies.

The actual rule: structure/function claims vs. disease claims

Dietary supplements are legally permitted to make “structure/function” claims — statements describing how a nutrient or ingredient supports the body’s normal structure or function (e.g., “supports healthy joints,” “helps maintain skin elasticity”). What they cannot legally do, without being regulated as an unapproved new drug, is make “disease claims” — statements that a product diagnoses, treats, cures, prevents, or mitigates a disease.

The regulation governing this distinction, 21 CFR 101.93, defines a “disease” as damage to an organ, part, structure, or system of the body such that it doesn’t function properly, or a state of health leading to that dysfunction — explicitly excluding classical nutrient-deficiency diseases (like scurvy) from this definition. It then lists specific criteria FDA uses to determine whether a statement counts as an implicit or explicit disease claim, including whether the product claims an effect on a specific disease, on the “characteristic signs or symptoms” of a disease, or — and this is the criterion most directly relevant to “anti-aging” marketing specifically — whether it claims an effect on “an abnormal condition associated with a natural state or process, if the abnormal condition is uncommon or can cause significant or permanent harm.”

That last criterion is worth sitting with, because it’s precisely the tension “anti-aging” claims live in. Aging is a normal, universal biological process — not itself a disease. But specific abnormal consequences that can accompany aging (certain forms of cognitive decline, osteoporosis-related fractures, macular degeneration, and so on) can be diseases in their own right. A supplement marketed to address the normal, gradual signs of aging (fine lines, some loss of skin elasticity) is generally on structure/function ground. The same supplement marketed as reversing, repairing, or preventing more serious, named age-related conditions is generally not — regardless of how the marketing frames the underlying ingredient.

The regulation also specifies exactly what triggers this distinction beyond direct wording: the product’s name, references to ingredients well known for treating disease, citations of disease-focused research presented in a way that implies treatment, and even “pictures, vignettes, symbols, or other means” can each independently turn an otherwise-permitted claim into a disease claim, depending on context. This matters because a lot of “anti-aging” marketing operates through implication — a stock photo of a person going from frail to vigorous, a citation to a study about a specific disease’s biology used to imply the product treats that disease — rather than a single explicit sentence a compliance reviewer could flag in isolation.

What this looks like when it goes wrong: the ReJuvenation case

The clearest, most concrete illustration of this line being crossed is a 2020 FTC enforcement action against the marketers of a product called ReJuvenation — made of amino acids and herbal extracts, sold via direct mail and online advertising between 2014 and 2016 (and beyond, under new ownership starting in 2016).

According to the FTC’s complaint, ReJuvenation’s marketing claimed the product could reverse the aging process and repair age-related damage to the body by increasing human growth hormone and stem cell counts, and that it could repair or reverse damage from a specific, named list of serious diseases: heart attacks, heart disease, blindness, brain damage from stroke, Alzheimer’s disease, Parkinson’s disease, deafness, and Crohn’s disease, among others. The complaint also cited claims of reduced wrinkle appearance and improved memory and cognitive functioning.

This is a textbook illustration of exactly the pattern 21 CFR 101.93 is written to catch: a product marketed with plausible-sounding structure/function language (“age-related damage,” “cellular repair”) that, on closer inspection, explicitly names specific diseases it claims to treat or reverse — moving well past permitted territory. The FTC’s resulting settlement (announced February 5, 2020) required $660,000 be made available for consumer refunds, permanently prohibited the defendants from making such claims without scientific substantiation, and imposed separate monetary judgments against the individual defendants (a $993,416 judgment against one defendant, suspended to $60,000 upon payment; a $2.4 million judgment against another, suspended to $600,000). The FTC’s own public statement on the case was blunt: “If you make those kinds of claims, you’d better have credible science to back it up or the FTC is coming for you.”

This case is now several years old, but the pattern it illustrates — vague “anti-aging” or “cellular repair” language sitting on top of a list of specific disease claims — is a durable one across the category, not a one-time incident.

What to look for, as a practical checklist

Based directly on the regulatory criteria above, a few concrete patterns are worth watching for in any anti-aging product’s marketing, including this site’s own future content:

• Named diseases or specific medical conditions appearing anywhere in the marketing (Alzheimer’s, heart disease, osteoporosis, macular degeneration, etc.) alongside a supplement claim — a strong signal the claim has moved from structure/function into disease-claim territory.
• Language like “reverse,” “repair,” “cure,” or “eliminate” applied to aging itself or its effects, rather than language like “support,” “maintain,” or “help with the appearance of.”
• Claims about affecting cellular-level processes tied to specific disease mechanisms (rather than general, normal-aging structure/function support) — particularly when paired with citations to disease-focused research.
• Before/after imagery, testimonials, or specific numeric claims (“reduces wrinkles by X%,” “reverses skin age by Y years”) that imply a treatment effect beyond ordinary cosmetic support.
• “Clinically proven” or “scientifically proven” language attached to disease-reversal claims specifically, as opposed to more modest, substantiated structure/function claims — the ReJuvenation case’s settlement order specifically targeted this combination.

None of this means every “anti-aging” product is making illegal claims, and it doesn’t mean structure/function claims are weak or meaningless — the collagen and NAD+ articles on this site cover real, if sometimes limited, human evidence for specific, appropriately framed claims in this exact category. The point of this article is narrower and more durable: “anti-aging” is a category where the gap between a legally and scientifically defensible claim and an overreaching one is unusually easy to cross without realizing it, and readers evaluating any product in this space — on this site or elsewhere — benefit from knowing specifically what that line looks like.

What we could not check

• We did not conduct a comprehensive survey of all FTC or FDA enforcement actions against anti-aging supplement marketers — the ReJuvenation case is presented as one clear, well-documented, and directly on-point illustration, not as the only or most recent such case; more recent enforcement actions likely exist and were not systematically reviewed here.
• We did not review FDA’s separate warning-letter enforcement track (as distinct from FTC’s consumer-protection settlements) for anti-aging-specific supplement cases in this pass.
• This article does not constitute legal advice, and nothing here should be read as a complete compliance checklist for any specific product’s marketing — it’s intended to help readers (and this site’s own future content) recognize the general pattern, not substitute for actual legal review of specific claims.

Our rating, and why

Not applicable. This article evaluates a regulatory framework, not a supplement, ingredient, or health claim, so this site’s evidence-classification scale doesn’t apply to it in the way it does elsewhere. Its purpose is to give readers (and this site’s own reviewers) a concrete, citable standard for recognizing when “anti-aging” language has moved from a legitimate structure/function claim into disease-claim territory — grounded directly in the actual federal regulation and a real enforcement case, not a general impression of “some claims seem exaggerated.”

---

Sources

1. U.S. Food and Drug Administration. 21 CFR 101.93 — Certain types of statements for dietary supplements. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-101/subpart-F/section-101.93 (read in full)
2. Federal Trade Commission. FTC Takes Action to Stop Anti-Aging “Cure-All” Marketers From Making Baseless Health Claims. Press release, February 5, 2020. https://www.ftc.gov/news-events/news/press-releases/2020/02/ftc-takes-action-stop-anti-aging-cure-all-marketers-making-baseless-health-claims (read in full)

Collagen is the best-known ingredient in this category, and also the clearest example of why “clinically proven” needs a follow-up question: proven by whom, and how well? A 2025 systematic review pooled 23 skin-focused trials and found real, measurable benefits overall — but that same review found the benefit disappeared once industry-funded and lower-quality trials were set aside, and the supplement industry has pushed back hard on how that review was conducted. Joint health tells a different, more reassuring story: a larger, more recent trial-sequential meta-analysis found small-to-moderate but consistent benefits for pain and function in osteoarthritis, less entangled with the funding question. Both things can be true about the same ingredient at once, and a reader deserves to know which claim they’re looking at.

The short version

• Collagen is the most abundant protein in the body, making up over 90% of skin’s structural mass. Natural collagen production declines with age (roughly 1–1.5% per year), which is the biological rationale marketers lean on for both skin and joint claims.
• For skin: a 2025 systematic review and meta-analysis (23 RCTs, 1,474 participants) found that when all trials were pooled, collagen supplementation showed statistically significant improvements in hydration, elasticity, and wrinkles — but when the researchers split trials by funding source, studies not funded by supplement or pharmaceutical companies showed no significant effect, and when they split by study quality, only the lower-quality studies showed a significant benefit for elasticity; the higher-quality studies showed no significant effect in any category. The authors’ own conclusion: “there is currently no clinical evidence to support the use of collagen supplements to prevent or treat skin aging.”
• That 2025 review is genuinely contested, not settled science, and it’s important to say so plainly. Industry groups (the Collagen Stewardship Alliance and the Gelatin Manufacturers of the World, among others) have publicly disputed it, alleging specific dose- and duration-reporting errors in several included trials and misclassification of some trials’ funding source. We have not independently re-verified either side’s claims trial-by-trial; the honest position is that this is an active scientific dispute, not a closed question in either direction.
• For joints, the picture is more consistent: a 2024 trial-sequential meta-analysis (35 RCTs, 3,165 patients, published in Osteoarthritis and Cartilage) found collagen derivatives produced small-to-moderate improvements in pain and function in people with osteoarthritis, with moderate-to-high certainty evidence and a good safety profile — a materially stronger evidence base than the skin claims, though still modest in effect size and mostly studied over less than six months.
• Collagen supplements are generally well tolerated, with no major documented drug interactions. The one real caution: as a protein source, high intakes add to total daily protein load, which matters specifically for people with advanced kidney disease who need to manage protein intake.
• “Collagen” isn’t one thing. Trials use different types (Type I, II, III), different sources (bovine, marine, porcine), different forms (hydrolyzed peptides vs. undenatured), and different doses (commonly 2.5–10 g/day for skin studies, though the 2025 review noted many of its included Asian trials used lower doses around 3 g/day) — a real source of inconsistency across the research base that any single verdict has to gloss over somewhat.

The skin claim: a genuinely contested meta-analysis

Collagen’s marketing centers heavily on skin — hydration, elasticity, wrinkle reduction, “glowing from within.” The strongest available evidence on this specific question is a 2025 systematic review and meta-analysis published in The American Journal of Medicine (Myung & Park), which pooled 23 randomized controlled trials with 1,474 total participants.

The topline, pooled result was positive: collagen supplementation was associated with statistically significant improvements in skin hydration, elasticity, and wrinkle reduction when every trial was averaged together. If the story stopped there, this would be a straightforward “Moderate” or better rating.

It doesn’t stop there. The same authors ran two further breakdowns of their own data:

• By funding source: trials not funded by pharmaceutical or supplement companies showed no statistically significant benefit in hydration, elasticity, or wrinkles. Trials that were industry-funded showed significant positive effects.
• By study quality: when the researchers restricted the analysis to higher-quality trials only, no significant effect remained in any category. Only the lower-quality subset of trials showed a significant benefit (specifically for elasticity).

Based on this, the authors concluded there is “currently no clinical evidence to support the use of collagen supplements to prevent or treat skin aging” — a notably stronger statement than the pooled headline number alone would suggest, and specifically because the pooled number appears to be carried by trials with a financial or methodological reason to find a positive result.

This finding has been publicly disputed, and that dispute deserves to be represented honestly rather than smoothed over. Industry groups responded directly to the published review:

• The Collagen Stewardship Alliance (CSA) alleged specific data-transcription errors in several included trials — for example, a trial’s actual dose or study duration recorded incorrectly in the meta-analysis’s data tables — and argued that some trials the review classified as “independent” actually had commercial ties, which (if true) would undermine the funding-based subgroup comparison.
• The Gelatin Manufacturers of the World (GROW) argued the review’s abstract and conclusion were internally inconsistent (acknowledging a significant pooled benefit, then concluding “no clinical evidence”), that the high/low quality classification method wasn’t disclosed using a named, validated tool, and that other meta-analyses (e.g., De Miranda et al. 2021) have found significant skin benefits at similar doses.
• Individual ingredient suppliers questioned whether pooling many different collagen types, sources, and doses together as one category was methodologically sound in the first place.

We have not independently re-checked the disputed dose/duration figures trial-by-trial, and we are not positioned to referee this dispute definitively. What we can say confidently: the existence of a documented funding-outcome pattern (independently-funded trials showing null results, industry-funded trials showing positive ones) is itself a meaningful, disclosable fact about this evidence base, consistent with a well-established pattern in nutrition research generally — and it’s a good enough reason on its own to rate the skin claim as Limited rather than Moderate, regardless of how the specific data-error allegations eventually resolve.

The joint claim: a stronger, less contested case

Collagen’s joint-health claims rest on different, and currently more consistent, evidence. A 2024 trial-sequential meta-analysis published in Osteoarthritis and Cartilage — a more rigorous statistical method than a standard meta-analysis, designed specifically to check whether the accumulated evidence has reached a reliable conclusion rather than a false-positive from too few trials — pooled 35 randomized controlled trials covering 3,165 patients (main analysis on 25 RCTs, 2,856 patients) with osteoarthritis.

The finding: collagen derivatives produced small-to-moderate effects on pain reduction, with moderate-to-high certainty of evidence, and similarly supported improvements in physical function. Safety was reassuring — collagen derivatives were not associated with an increased risk of adverse events or trial withdrawal compared to control. The main caveat the authors themselves raised: most included trials followed patients for under six months, so longer-term efficacy and durability of benefit remain open questions.

Individual, more recent randomized trials in knee osteoarthritis specifically have reported reductions in pain scores and inflammatory markers (CRP, ESR) alongside functional improvement, consistent with the pooled picture. This is a meaningfully different evidence situation than the skin literature: while individual trials still vary in collagen type, dose, and source, the joint-health signal has not (so far) been shown to collapse when isolating higher-quality or independently funded trials the way the skin signal did in the 2025 review — though we note that a funding-source-specific breakdown for the joint literature specifically, comparable to what Myung & Park ran for skin, is not something we independently verified exists or was checked here.

One compliance-relevant point worth naming directly: osteoarthritis is a diagnosed medical condition, not a cosmetic concern. Any future product content citing this joint-health evidence needs to describe supporting “joint comfort” or “joint function” rather than language that could be read as treating or curing a diagnosed disease — the same disease-claim line this site’s Editorial Policy holds every ingredient to, regardless of how solid the underlying evidence is.

What “collagen” actually means as an ingredient category

Collagen is the most abundant protein in the human body and the primary structural protein in skin, providing its mechanical integrity; skin’s own collagen synthesis is estimated to decline by roughly 1–1.5% per year with age, which is the plausible biological mechanism behind both the skin and joint marketing claims. But “collagen supplement” is not one standardized product: trials studied here used different collagen types (Type I is most common in skin studies; Type I/III and Type II both appear in joint studies), different animal or marine sources, different degrees of processing (hydrolyzed peptides being the most common, broken into smaller, more absorbable pieces, versus undenatured collagen used in some joint-specific trials), and different daily doses — commonly in the 2.5–10 g/day range for skin research, though the 2025 review noted many of its Asian-conducted trials used doses closer to 3 g/day, which industry critics flagged as potentially not representative of typical Western consumption patterns. This variability is a genuine limitation of drawing one clean verdict from “collagen” as a single category, and it cuts both ways: it means a single negative or positive trial doesn’t necessarily generalize to every product on shelves.

What we could not check

• We did not independently re-verify the specific data-transcription allegations (dose, duration, funding classification) that industry groups raised against the 2025 skin meta-analysis — we’re reporting that a documented, public dispute exists and summarizing both sides’ positions, not adjudicating whose figures are correct.
• We did not conduct our own funding-source breakdown of the 2024 joint-health meta-analysis the way Myung & Park did for skin — we don’t know whether the same industry-funding pattern would appear if someone ran that analysis on the joint literature, and we’re not presenting the joint evidence as immune to the same possible bias, only as not yet shown to have it.
• We did not independently assess any single branded collagen product’s type, source, dose, or third-party testing — this article covers collagen as a researched ingredient category, not a specific product.
• We did not evaluate collagen’s other marketed uses (hair, nail, gut, bone density beyond osteoarthritis specifically) in this article.

Our rating, and why

For skin hydration, elasticity, and wrinkles: Limited. The largest available meta-analysis found a positive pooled effect that disappeared under funding-source and study-quality subgroup analysis — a documented pattern, not a hypothetical concern — even though the review’s methodology has been publicly and specifically disputed by industry groups. Limited reflects a real, unresolved dispute over a genuinely thin independent evidence base, not a dismissal of collagen outright.

For joint pain and function in osteoarthritis: Moderate. A larger, more methodologically rigorous meta-analysis found small-to-moderate, statistically credible benefits with a good safety profile, and — as far as we could determine — without the same funding-outcome pattern documented in the skin literature. Still Moderate rather than Strong because effect sizes are modest and most trials are short-term.

---

Sources

1. Myung SK, Park Y. Effects of Collagen Supplements on Skin Aging: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. The American Journal of Medicine. 2025. doi: 10.1016/j.amjmed.2025.04.034. https://www.amjmed.com/article/S0002-9343(25)00283-9/abstract
2. Stern C. Industry pushes back on meta-analysis concluding collagen supplements show no benefit for skin aging. NutraIngredients. Published 2025-08-26. https://www.nutraingredients.com/Article/2025/08/26/industry-reacts-to-meta-analysis-concluding-collagen-supplements-show-no-proven-benefit-for-skin-aging/ (secondary source — summarizes CSA and GROW industry responses to source 1; underlying trial-level dispute not independently re-verified)
3. Liang CW, et al. Efficacy and safety of collagen derivatives for osteoarthritis: A trial sequential meta-analysis. Osteoarthritis and Cartilage. 2024 May. PMID: 38218227. https://www.oarsijournal.com/article/S1063-4584(24)00004-9/fulltext (read via abstract and secondary summaries)

NAD+ (nicotinamide adenine dinucleotide) precursors are the fastest-growing, least human-evidenced ingredient class in the healthy-aging category — and also one with an unusually eventful recent regulatory history worth knowing about before anything else. The core biological story is genuinely interesting: NAD+ is a molecule every cell needs for energy metabolism and DNA repair, and levels measurably decline with age. The gap is between that plausible mechanism and what’s actually been shown to happen when a healthy adult takes NMN or NR by mouth — which, so far, is reliably “your blood NAD+ goes up,” and much more thinly “and something clinically meaningful happens as a result.”

The short version

• NAD+ is a real, essential molecule, and its age-related decline is genuinely documented — it’s not a fabricated premise. NAD+ serves as a co-substrate for enzymes (sirtuins, PARPs) implicated in DNA repair and cellular energy metabolism, both processes that decline with age.
• NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are the two most-marketed NAD+ precursors, and they are not the same ingredient with different names — they have different regulatory histories, which matters. NR has been recognized as Generally Recognized As Safe (GRAS) by the FDA for use in food and has an established New Dietary Ingredient (NDI) history. NMN’s regulatory path has been considerably rockier: in November 2022, the FDA determined NMN was excluded from the legal definition of a “dietary supplement” (on drug-exclusion grounds, tied to a separate company’s investigational NMN drug development), a determination the Natural Products Association sued over — the FDA reversed course and confirmed NMN’s lawful status as a supplement ingredient in September 2025. That’s a three-year period during which NMN’s legal supplement status was genuinely unsettled, not a minor technicality.
• Both NMN and NR reliably raise blood NAD+ levels in human trials — this specific, narrow claim is well-supported and not seriously contested.
• But two independent 2024 systematic reviews and meta-analyses of NMN specifically found no significant effect on glucose control or lipid metabolism — the clinically relevant outcomes most directly tied to metabolic-aging claims. One (12 studies, 513 participants, Critical Reviews in Food Science and Nutrition) found no effect on blood lipids or glycemic biomarkers. A second, independent review (8 RCTs, 342 middle-aged/older adults, Current Diabetes Reports) reached the same conclusion: no significant benefit on fasting glucose, fasting insulin, HbA1c, insulin resistance, or lipid profile.
• One honest counter-nuance, not omitted: a smaller but well-designed 2022 randomized trial (80 healthy middle-aged adults, GeroScience) found that NMN at 600–900 mg/day (but not 300 mg/day) produced a statistically significant improvement in six-minute walk test distance and self-reported quality of life (SF-36) after 60 days. This is a real, positive functional finding — but it’s one trial, in one population, not yet replicated at this scale, and it measured a different outcome (physical function) than the null metabolic-biomarker findings above.
• NR’s human evidence base looks broadly similar in shape: well-tolerated, reliably raises NAD+, but “few human studies have assessed the impact of NAD+-boosting strategies for promoting healthy aging, and evidence suggesting improvements in quality of life remains sparse,” per researchers reviewing the space directly. Trials in cognitive decline and Alzheimer’s biomarkers are underway but not yet conclusive.

What NAD+ actually is, and why the marketing story is at least plausible

NAD+ is not a fringe or invented target — it’s a coenzyme every human cell needs, involved in converting food into cellular energy and supporting DNA-repair enzymes (sirtuins and PARPs) that have their own extensive, separate research literature in aging biology. NAD+ levels do decline with age in measured human tissue, which is the real biological premise the “boost your NAD+” marketing category is built on. NMN and NR are both precursor molecules — the body converts them into NAD+ through different metabolic pathways — positioned as a more direct or efficient route to raising NAD+ than, for instance, niacin (vitamin B3) supplementation, an older and separately studied approach to the same target.

This is worth stating plainly because it distinguishes this category from something like homeopathy: the mechanism isn’t implausible, and the “levels decline, precursor supplementation raises them back up” first step of the story is genuinely true in human trials. The open question isn’t whether NAD+ can be raised — it’s whether raising it produces a health benefit large enough, and reliable enough, to justify the claims built on top of it.

NMN: a real regulatory rollercoaster, and a metabolic-benefit signal that hasn’t held up

NMN’s regulatory status is a genuinely unusual story for a dietary supplement ingredient, and worth including here because it’s directly relevant to how confidently any product built on it can be marketed. A company had filed an Investigational New Drug (IND) application to develop NMN as a prescription drug; under the Dietary Supplement Health and Education Act’s “drug exclusion clause,” an ingredient that has been authorized for investigation as a new drug generally cannot also be sold as a dietary supplement ingredient — the FDA applied that logic to NMN broadly in November 2022, reversing an earlier 2022 approval of one company’s New Dietary Ingredient notification for it. The Natural Products Association sued, and separately filed an amended citizen petition, arguing the exclusion was misapplied. In two letters dated 29 September 2025, the FDA reversed its position and confirmed that NMN is not excluded from the dietary supplement definition after all — restoring its legal footing roughly three years after the exclusion began. The reversal turned on the drug-exclusion clause’s own “race to market” provision: the FDA concluded there was sufficient evidence that NMN had been marketed as a dietary supplement in the United States before it was authorized for investigation as a drug, which is the specific carve-out that keeps an ingredient eligible.

On the science specifically: two independent systematic reviews and meta-analyses published in 2024, using different (though partially overlapping) sets of trials, both concluded NMN supplementation had no significant effect on the metabolic outcomes most tied to its “anti-aging”/metabolic-health marketing — fasting glucose, fasting insulin, HbA1c, insulin resistance markers, and lipid profile. This is a meaningfully consistent null finding across two separate research teams, not a single underpowered study.

At the same time, a smaller, well-designed dose-ranging trial (80 healthy middle-aged adults, four arms: placebo, 300/600/900 mg NMN daily, 60 days) found that the 600 mg and 900 mg groups — but not 300 mg — showed statistically significant improvement in six-minute walk test distance and self-reported quality of life compared to placebo, alongside the expected rise in blood NAD+. This is a genuinely different kind of outcome than the metabolic-biomarker meta-analyses above (physical function and subjective wellbeing, not glucose/lipids), so it isn’t a direct contradiction of the null findings — but it is the single most positive, best-designed human efficacy signal in the NMN literature to date, and it deserves to be named rather than buried under the two null meta-analyses. The honest summary: NMN measurably raises NAD+ and, in at least one solid trial at adequate doses, measurably improved a functional outcome — but has not yet been shown, across the larger accumulated evidence, to move the metabolic biomarkers most central to its marketing.

NR: safer regulatory footing, similarly thin outcome data

Nicotinamide riboside has a more settled regulatory history than NMN — its crystalline chloride form (marketed under the brand name Niagen) has GRAS status for food use and an established New Dietary Ingredient Notification history, without the drug-exclusion dispute NMN went through. Human trials confirm NR is well tolerated at doses tested up to at least 3,000 mg/day, with no evidence of toxicity, and it reliably and measurably raises blood NAD+ in healthy middle-aged and older adults, an effect demonstrated in randomized, placebo-controlled, crossover trials.

Where NR’s evidence base is currently thinnest is the same place NMN’s is: translating a reliable NAD+ increase into a demonstrated health or aging-relevant outcome. Researchers actively working in this space describe it plainly — few human studies have specifically assessed whether NAD+-boosting strategies improve healthy-aging outcomes, and evidence for quality-of-life improvement remains sparse. Ongoing trials are testing NR in more specific contexts (cognitive decline and Alzheimer’s disease biomarkers, Parkinson’s disease, post-COVID persistent symptoms) — these are real, registered trials worth watching, but they are not yet completed, positive evidence as of this writing.

What we could not check

• We did not independently pull and read the full text of either 2024 NMN meta-analysis (Critical Reviews in Food Science and Nutrition; Current Diabetes Reports) — findings are drawn from abstracts and secondary summaries, not a full methods-and-results read.
• The NMN regulatory timeline was re-verified on 2026-08-08 (pre-approval verification pass) against multiple independent sources — a law-firm regulatory analysis (Venable LLP), the Natural Products Association’s own announcement, and trade-press coverage — which confirmed all load-bearing details: the November 2022 drug-exclusion determination, the two FDA letters dated 29 September 2025, the NPA lawsuit and amended citizen petition, and the “race to market” reasoning behind the reversal. We still have not read the primary FDA correspondence directly on FDA.gov — the letters were issued to specific companies rather than published as a general notice, so this remains multi-source secondary verification rather than a primary-document read.
• We did not review the completed or ongoing NR trials in Alzheimer’s disease, Parkinson’s disease, or post-COVID recovery in any depth — these are named as active areas of research, not summarized as evidence one way or the other, since they are not yet complete.
• We did not assess any specific branded NMN or NR product’s purity, third-party testing, or actual delivered dose — a documented concern in this ingredient category generally, since NMN in particular is a newer, less standardized supply chain than most ingredients covered on this site; this article covers the researched molecules, not any specific product.

Our rating, and why

Limited. The mechanistic premise (NAD+ declines with age; NMN/NR reliably restore blood NAD+ levels) is genuinely well-supported and not in serious dispute. But the two largest, most recent, independent meta-analyses of NMN’s most clinically relevant metabolic outcomes both found no significant effect — a consistent null result, not a data gap. The one clearly positive human efficacy signal (the 2022 GeroScience dose-ranging trial’s functional/quality-of-life findings) is real and worth taking seriously, but it’s a single trial that has not yet been replicated at the same scale as the null findings it sits alongside. NR’s picture is similar in shape: safe, reliably raises NAD+, but with even less outcome-level human data currently published. This combination — real mechanism, reliable biomarker movement, but not-yet-demonstrated clinical benefit at scale — is close to the textbook definition of a Limited rating on this site’s scale, and is also, unusually for this category, complicated by NMN’s genuinely unsettled recent regulatory history.

---

Sources

1. Zhang R, Poon C, Wong M. Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism for adults: a systematic review with meta-analysis on randomized controlled trials. Critical Reviews in Food Science and Nutrition. 2024 Aug 8. PMID: 39116016. https://pubmed.ncbi.nlm.nih.gov/39116016/ (read via abstract and secondary summaries)
2. Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials. Current Diabetes Reports. 2024 Nov. PMID: 39531138. https://pubmed.ncbi.nlm.nih.gov/39531138/ (read via abstract and secondary summaries)
3. Yi L, Maier AB, Tao R, et al. The Efficacy and Safety of β-Nicotinamide Mononucleotide (NMN) Supplementation in Healthy Middle-Aged Adults: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Dependent Clinical Trial. GeroScience. 2023;45:29-43. PMID: 36482258. https://pubmed.ncbi.nlm.nih.gov/36482258/ (read via abstract and secondary summaries)
4. Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. 2018;9:1286. https://www.nature.com/articles/s41467-018-03421-7 (read via abstract and secondary summaries)
5. Natural Products Association / trade press coverage of FDA’s NMN dietary-supplement status reversal (Sept. 2025), including NutraIngredients and dicentra regulatory summaries. FDA’s original letters were not independently accessed by us — see editorial notes.